Edwards Lifesciences' stock surged 5.24% in pre-market trading following the release of stronger-than-expected first-quarter financial results and an upward revision to its full-year outlook.

The medical device company reported quarterly sales and profit that exceeded analyst estimates, driven by robust demand for its artificial heart valves. Notably, sales of its transcatheter aortic valve replacement (TAVR) device rose 14.4% year-over-year to $1.2 billion, surpassing expectations.

Based on this performance, the company raised its annual adjusted profit forecast to a range of $2.95 to $3.05 per share, from a prior view of $2.90 to $3.05. It also increased its annual sales growth guidance to 9% to 11%, up from the previous range of 8% to 10%.